Expert Opin Biol Ther. 2024 Jun;24(6):425-432. doi: 10.1080/14712598.2024.2371034. Epub 2024 Jun 29.
ABSTRACT
INTRODUCTION: CAR T cells have generated great excitement due to their remarkable clinical response rates in selected hematologic malignancies. However, these engineered immune cells are living drugs which are hard to control after administration.
AREAS COVERED: We discuss small molecule-regulated switch systems which can potentially be used to control CAR T cell function within the patient, as well as the most important obstacles in the CAR T cell field, which might be overcome with those switch systems.
EXPERT OPINION: There is an urgent need to develop advanced switch systems. Once available, we expect that they will open up new avenues for future CAR T cell generations.
PMID:38943466 | DOI:10.1080/14712598.2024.2371034
